Humana (NYSE:HUM) Price Target Raised to $300.00 at BMO Capital Markets

Humana (NYSE:HUM) had its price target lifted by BMO Capital Markets from $290.00 to $300.00 in a research note released on Friday, November 10th. They currently have an outperform rating on the insurance provider’s stock.

HUM has been the topic of several other reports. Royal Bank Of Canada reaffirmed a sector perform rating and set a $242.00 price target (down from $245.00) on shares of Humana in a research report on Thursday, November 9th. Credit Suisse Group reiterated an outperform rating and issued a $260.00 price objective (up from $250.00) on shares of Humana in a report on Thursday, August 3rd. Deutsche Bank upped their price objective on shares of Humana from $234.00 to $243.00 and gave the company a hold rating in a report on Monday, August 7th. Oppenheimer upped their price objective on shares of Humana from $236.00 to $255.00 and gave the company an outperform rating in a report on Thursday, August 3rd. Finally, BidaskClub downgraded shares of Humana from a hold rating to a sell rating in a research note on Thursday, August 17th. Thirteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Humana has a consensus rating of Hold and an average price target of $252.81.

Humana (HUM) opened at $250.13 on Friday. The stock has a market cap of $34,359.28, a P/E ratio of 20.52, a P/E/G ratio of 1.65 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.61 and a current ratio of 1.61. Humana has a 1-year low of $186.25 and a 1-year high of $264.56.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the previous year, the firm posted $3.18 earnings per share. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. equities analysts forecast that Humana will post 11.63 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be issued a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.64%. Humana’s dividend payout ratio (DPR) is currently 12.59%.

In other news, VP Timothy S. Huval sold 7,803 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the transaction, the vice president now owns 8,831 shares of the company’s stock, valued at $2,279,634.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the completion of the transaction, the insider now owns 18,042 shares of the company’s stock, valued at approximately $4,672,878. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Humana by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock valued at $2,380,366,000 after buying an additional 157,868 shares during the last quarter. FMR LLC raised its holdings in Humana by 29.3% in the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after buying an additional 1,479,210 shares during the last quarter. Capital Research Global Investors raised its holdings in Humana by 9.7% in the 2nd quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock valued at $940,182,000 after buying an additional 346,069 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Humana by 1.5% in the 2nd quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock valued at $657,157,000 after buying an additional 39,400 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Humana by 74.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock valued at $664,921,000 after buying an additional 1,161,661 shares during the last quarter. Institutional investors and hedge funds own 94.18% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Humana (NYSE:HUM) Price Target Raised to $300.00 at BMO Capital Markets” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/bmo-capital-markets-increases-humana-inc-hum-price-target-to-300-00/1775808.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with our FREE daily email newsletter.

 


Latest News

Stephen Strasburg May Skip All-Star Games in the Future
Stephen Strasburg May Skip All-Star Games in the Future
Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks


Leave a Reply

 
© 2006-2017 BBNS.